Trophogen, Inc. is a biotechnology company based in Rockville, Maryland. The company was founded in 2001 with Series A funding from Toucan Capital, focusing on the development of human and bovine high affinity glycoprotein hormone and related growth factor superagonist analogs for human infertility and animal superovulation, as well as targeted therapy and imaging of thyroid, ovarian, breast, prostate and testicular cancers.